Mechanism of IL-10 Pathway-mediated Regulatory B Cell Dysfunction in Osteoarthritis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06227195

Enrollment

Registered

2024-01-26

Start date

2019-01-01

Completion date

2021-12-31

Last updated

2024-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Arthritis, Osteoarthritis

Brief summary

Our previous work has shown that Treg function is impaired in OA patients, but the cause of Treg deficiency has not been investigated. Since Breg has been shown to promote Treg differentiation and tissue repair, it is highly likely that the absence of the immunomodulatory effect of Breg in OA patients leads to impaired Treg differentiation. Based on the above data, we hypothesized that Breg plays a protective role in the course of OA by regulating T cell composition and promoting Treg differentiation through the secretion of anti-inflammatory factor IL-10

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

Patients who met the American College of Rheumatology diagnostic criteria for OA \-

Exclusion criteria

* Patients with trauma, other forms of arthritis such as rheumatoid arthritis, psoriatic arthritis or spondyloarthritis, and other active inflammatory diseases

Design outcomes

Primary

Measure	Time frame	Description
Number of Breg	4 and 8 weeks after DMM	Regulatory B cells

Secondary

Measure	Time frame	Description
Cytokine secretion by T cells	4 and 8 weeks after DMM	Regulatory T cells

Countries

China

Outcome results